Clinical Trial Update: Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating autologous T cells engineered with retroviral vectors to express TCRs against patient-specific neoantigens in hematologic mali…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Hematologic Neoplasms

Drugs mentioned

• Autologous neoantigen-specific TCR-T cells (Neoantigen-specific T-cell receptor engineered T cells)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Malignancy, Hematologic, Neoplasms, Hematologic | Phase 1 | Status: RECRUITING